Eddie Hu, MD
Hematology-Oncology · Alhambra, CANPI 1871537738
Payments from drug & device makers
What this record shows
This record is dominated by other: $1,548 of the $1,839 with a category attached, or 84.2%. Novartis accounts for 86.6% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2021 at $1,062 and has fallen 98.3% since, to $18 in 2025. That places this record below the midpoint for hematology-oncology clinicians in CA, where the typical reported total is $1,839.
Across 29 payments — averaging $63.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$2K
- Pharmacyclics LLC, An Abbvie Company$100
- AstraZeneca$40
- Pfizer$40
- Johnson & Johnson$22
- Merck$18
- plus $27 from 2 others
What the payments were for
- Food & beverage$1317%
- Education$1609%
- Other$1,54884%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 20 | $1,592 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $100 |
| AstraZeneca | 2 | $40 |
| Pfizer | 2 | $40 |
| Johnson & Johnson | 1 | $22 |
| Merck | 1 | $18 |
| Beigene USA, Inc. | 1 | $14 |
| Myriad Genetic Laboratories, Inc. | 1 | $12 |
How this compares
$1,839 in reported general payments places this provider in the 50th percentile of 53 hematology-oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TagrissoOsimertinib Mesylate | 206 | $3,438,301 |
| ImbruvicaIbrutinib | 29 | $672,974 |
| TepmetkoTepotinib Hcl | 21 | $513,278 |
| RevlimidLenalidomide | 28 | $445,144 |
| KisqaliRibociclib Succinate | 23 | $388,950 |
| PromactaEltrombopag Olamine | 28 | $360,894 |
| XtandiEnzalutamide | 23 | $320,713 |
| JakafiRuxolitinib Phosphate | 15 | $279,738 |
| AlecensaAlectinib Hcl | 12 | $232,255 |
| XgevaDenosumab | 66 | $214,257 |
| CalquenceAcalabrutinib Maleate | 14 | $213,856 |
| BrukinsaZanubrutinib | 15 | $201,818 |
| MekinistTrametinib Dimethyl Sulfoxide | 12 | $185,997 |
| ReblozylLuspatercept-Aamt | 13 | $180,273 |
| ErleadaApalutamide | 12 | $179,239 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTagrisso, Calquence | $40 | $3,652,157220 claims |
| NovartisKisqali, Promacta, Mekinist, Tafinlar | $1,592 | $1,105,43575 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $100 | $672,97429 claims |
| Johnson & JohnsonErleada, Procrit, Xarelto | $22 | $350,34759 claims |
| PfizerInlyta, Eliquis | $40 | $258,423122 claims |
| Beigene USA, Inc.Brukinsa | $14 | $201,81815 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 53 hematology-oncology providers in California.
Other hematology-oncology in Alhambra
- James BerensonWest Hollywood$1M
- Ari BaronSan Francisco$705K
- Jeffrey WolfSan Francisco$407K
- Haresh JhangianiFountain Valley$77K
- Mark ScholzMarina del Rey$62K
- Derrick SuFountain Valley$53K
- Peyman Salimi-TariFountain Valley$49K
- Janet PanFountain Valley$46K
- Bertrand TuanSan Francisco$45K
- Brian ChoiRiverside$35K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.